A Randomized, Multicenter, Open Phase III Study Comparing the Postoperative Use of Zoledronic Acid Versus no Treatment in Patients With Histological Tumor Residuals After Preoperative Anthracycline and Taxane Containing Chemotherapy for Primary Breast Cancer

Trial Profile

A Randomized, Multicenter, Open Phase III Study Comparing the Postoperative Use of Zoledronic Acid Versus no Treatment in Patients With Histological Tumor Residuals After Preoperative Anthracycline and Taxane Containing Chemotherapy for Primary Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms NaTaN
  • Most Recent Events

    • 17 Jun 2016 Primary endpoint has not been met. (Disease-free survival (DFS)), as per results published in the European Journal of Cancer.
    • 17 Jun 2016 Results published in the European Journal of Cancer
    • 04 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top